

Jordi Navarro

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5835157/publications.pdf>

Version: 2024-02-01

70
papers

2,062
citations

304743

22
h-index

254184

43
g-index

78
all docs

78
docs citations

78
times ranked

3590
citing authors

#	ARTICLE	IF	CITATIONS
1	Epidemiological trends of HIV/HCV coinfection in Spain, 2015–2019. <i>HIV Medicine</i> , 2022, 23, 705-716.	2.2	14
2	Impact of tenofovir on SARS-CoV-2 infection and severe outcomes among people living with HIV: a propensity score-matched study. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 2265-2273.	3.0	13
3	Screening for asymptomatic STIs in HIV-infected men who have sex with men. <i>Sexually Transmitted Infections</i> , 2021, 97, 170-171.	1.9	2
4	HCV eradication with IFN-based therapy does not completely restore gene expression in PBMCs from HIV/HCV-coinfected patients. <i>Journal of Biomedical Science</i> , 2021, 28, 23.	7.0	6
5	Low frequency of cytomegalovirus (CMV) disease despite high prevalence of CMV viraemia in patients with advanced HIV infection: a clinical and immunological 48-week follow-up study. <i>HIV Medicine</i> , 2021, 22, 682-689.	2.2	3
6	Peripheral and lung resident memory T cell responses against SARS-CoV-2. <i>Nature Communications</i> , 2021, 12, 3010.	12.8	111
7	Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure. <i>Antiviral Research</i> , 2020, 174, 104694.	4.1	39
8	Incidencia de neoplasias en una cohorte española de pacientes con infección por el virus de la inmunodeficiencia humana. <i>Medicina Clínica</i> , 2020, 155, 288-294.	0.6	3
9	Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE Trial. <i>Journal of Infectious Diseases</i> , 2020, 222, S8-S19.	4.0	8
10	Effects of Hepatitis C Virus (HCV) Eradication on Bone Mineral Density in Human Immunodeficiency Virus/HCV-Coinfected Patients. <i>Clinical Infectious Diseases</i> , 2020, 73, e2026-e2033.	5.8	2
11	Primary resistance to integrase strand transfer inhibitors in Spain using ultrasensitive HIV-1 genotyping. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3517-3524.	3.0	6
12	Lipidomics Reveals Reduced Inflammatory Lipid Species and Storage Lipids after Switching from EFV/FTC/TDF to RPV/FTC/TDF: A Randomized Open-Label Trial. <i>Journal of Clinical Medicine</i> , 2020, 9, 1246.	2.4	9
13	Effectiveness of boosted darunavir plus rilpivirine in patients with long-lasting HIV-1 infection: DARIL study. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1955-1960.	3.0	4
14	Exploration of clients living with HIV needs for reporting on experiences with sex. <i>Australian Journal of Cancer Nursing</i> , 2020, 22, 570-576.	1.6	4
15	Effects of Eradication of HCV on Cardiovascular Risk and Preclinical Atherosclerosis in HIV/HCV-Coinfected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 83, 292-300.	2.1	5
16	Expression of CD20 after viral reactivation renders HIV-reservoir cells susceptible to Rituximab. <i>Nature Communications</i> , 2019, 10, 3705.	12.8	38
17	Latency reversal agents affect differently the latent reservoir present in distinct CD4+ T subpopulations. <i>PLoS Pathogens</i> , 2019, 15, e1007991.	4.7	119
18	Discontinuation of dolutegravir, elvitegravir/cobicistat and raltegravir because of toxicity in a prospective cohort. <i>HIV Medicine</i> , 2019, 20, 237-247.	2.2	32

#	ARTICLE	IF	CITATIONS
19	Simplification of Antiretroviral Treatment from Darunavir/Ritonavir Monotherapy to Darunavir/Cobicistat Monotherapy: Effectiveness and Safety in Routine Clinical Practice. <i>AIDS Research and Human Retroviruses</i> , 2019, 35, 513-518.	1.1	20
20	Effectiveness of Once/Day Dolutegravir Plus Boosted Darunavir as a Switch Strategy in Heavily Treated Patients with Human Immunodeficiency Virus. <i>Pharmacotherapy</i> , 2019, 39, 501-507.	2.6	15
21	Low nadir CD4+ T-cell counts predict gut dysbiosis in HIV-1 infection. <i>Mucosal Immunology</i> , 2019, 12, 232-246.	6.0	56
22	Switching From a Protease Inhibitor-based Regimen to a Dolutegravir-based Regimen: A Randomized Clinical Trial to Determine the Effect on Peripheral Blood and Ileum Biopsies From Antiretroviral Therapy-suppressed Human Immunodeficiency Virus-infected Individuals. <i>Clinical Infectious Diseases</i> , 2019, 69, 1320-1328.	5.8	23
23	Immune reconstitution inflammatory syndrome in HIV-infected patients with <i>Pneumocystis jirovecii</i> pneumonia. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2018, 36, 621-626.	0.5	13
24	Memory B cell dysregulation in HIV-1-infected individuals. <i>Aids</i> , 2018, 32, 149-160.	2.2	11
25	Farmacología de Symtuza® (DRV/c/FTC/TAF). <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2018, 36, 10-16.	0.5	1
26	Brief Report: Effectiveness of Trichloroacetic Acid vs. Electrocautery Ablation for the Treatment of Anal High-Grade Squamous Intraepithelial Lesion in HIV-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 79, 612-616.	2.1	8
27	Human Immunodeficiency Virus/Hepatitis C Virus Coinfection in Spain: Elimination Is Feasible, but the Burden of Residual Cirrhosis Will Be Significant. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofx258.	0.9	21
28	Neurocognitive safety after 96 weeks on dual therapy with atazanavir/ritonavir plus lamivudine: results of the neurocognitive substudy of the SALT randomized clinical trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2444-2451.	3.0	6
29	Acute Leg Ischaemia in an HIV-Infected Patient Receiving Antiretroviral Treatment. <i>Antiviral Therapy</i> , 2017, 22, 89-90.	1.0	10
30	Hepatic safety of maraviroc in HIV-1-infected patients with hepatitis C and/or B co-infection. The Maraviroc Cohort Spanish Group. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2017, 35, 493-498.	0.5	3
31	Risk factors of high-grade anal intraepithelial neoplasia recurrence in HIV-infected MSM. <i>Aids</i> , 2017, 31, 1245-1252.	2.2	15
32	Genotypic tropism testing of proviral DNA to guide maraviroc initiation in aviraemic subjects: 48-week analysis of results from the PROTEST study. <i>HIV Medicine</i> , 2017, 18, 482-489.	2.2	1
33	Hepatic safety of maraviroc in HIV-1-infected patients with hepatitis C and/or B co-infection. The Maraviroc Cohort Spanish Group. <i>Enfermedades Infecciosas Y Microbiología Clínica (English Ed)</i> , 2017, 35, 491-496.	0.3	0
34	The role of oncogenic human papillomavirus determination for diagnosis of high-grade anal intraepithelial neoplasia in HIV-infected MSM. <i>Aids</i> , 2017, 31, 2227-2233.	2.2	27
35	APPLICATION OF CELL-OF-ORIGIN SUBTYPES DETERMINED BY DIGITAL GENE EXPRESSION IN HIV-RELATED DIFFUSE LARGE B-CELL LYMPHOMAS. <i>Hematological Oncology</i> , 2017, 35, 156-157.	1.7	0
36	Epstein-Barr virus load in plasma is an early biomarker of HIV-related lymphomas. <i>Hematological Oncology</i> , 2017, 35, 330-330.	1.7	0

#	ARTICLE	IF	CITATIONS
37	Efficacy and safety of direct antiviral agents in a cohort of cirrhotic HCV/HIV-coinfected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2850-2856.	3.0	13
38	A Novel Single-Cell FISH-Flow Assay Identifies Effector Memory CD4 ⁺ T cells as a Major Niche for HIV-1 Transcription in HIV-Infected Patients. <i>MBio</i> , 2017, 8, .	4.1	105
39	Simplification to dual therapy (atazanavir/ritonavir+lamivudine) versus standard triple therapy [atazanavir/ritonavir+two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study). <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 246-253.	3.0	57
40	Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial. <i>Clinical Infectious Diseases</i> , 2017, 65, 2112-2118.	5.8	88
41	Sensitive quantification of the HIV-1 reservoir in gut-associated lymphoid tissue. <i>PLoS ONE</i> , 2017, 12, e0175899.	2.5	50
42	Evolution of acute hepatitis C virus infection in a large European city: Trends and new patterns. <i>PLoS ONE</i> , 2017, 12, e0187893.	2.5	8
43	Profile of once-daily darunavir/cobicistat fixed-dose combination for the treatment of HIV/AIDS. <i>HIV/AIDS - Research and Palliative Care</i> , 2016, Volume 8, 175-182.	0.8	10
44	Impact of Low-Level Viraemia on Virological Failure in HIV-1-Infected Patients with Stable Antiretroviral Treatment. <i>Antiviral Therapy</i> , 2016, 21, 345-352.	1.0	14
45	Improvement of BMD after Switching from Lopinavir/R Plus Two Nucleos(T)ide Reverse Transcriptase Inhibitors to Lopinavir/R Plus Lamivudine: OLE-LIP Substudy. <i>HIV Clinical Trials</i> , 2016, 17, 89-95.	2.0	2
46	Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV+HCV co-infected patients: final results of the Spanish BOC HIV+HCV Study. <i>International Journal of Infectious Diseases</i> , 2016, 53, 46-51.	3.3	2
47	The effectiveness of electrocautery ablation for the treatment of high-grade anal intraepithelial neoplasia in HIV-infected men who have sex with men. <i>HIV Medicine</i> , 2016, 17, 524-531.	2.2	33
48	Human Immunodeficiency Virus/Hepatitis C Virus Coinfection in Spain: Prevalence and Patient Characteristics. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw059.	0.9	34
49	Gut Microbiota Linked to Sexual Preference and HIV Infection. <i>EBioMedicine</i> , 2016, 5, 135-146.	6.1	328
50	Short-term Treatment With Interferon Alfa Diminishes Expression of HIV-1 and Reduces CD4 ⁺ T-Cell Activation in Patients Coinfected With HIV and Hepatitis C Virus and Receiving Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2016, 213, 1008-1012.	4.0	36
51	Reduced darunavir dose is as effective in maintaining HIV suppression as the standard dose in virologically suppressed HIV-infected patients: a randomized clinical trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1139-1145.	3.0	21
52	Liver stiffness and aspartate aminotransferase levels predict the risk for liver fibrosis progression in hepatitis C virus/HIV coinfected patients. <i>HIV Medicine</i> , 2015, 16, 211-218.	2.2	18
53	Dual treatment with atazanavir+ritonavir plus lamivudine versus triple treatment with atazanavir+ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 775-784.	9.1	122
54	Dual treatment with lopinavir+ritonavir plus lamivudine versus triple treatment with lopinavir+ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 785-792.	9.1	131

#	ARTICLE	IF	CITATIONS
55	The Lipid-Lowering Effect of Tenofovir/Emtricitabine: A Randomized, Crossover, Double-Blind, Placebo-Controlled Trial. <i>Clinical Infectious Diseases</i> , 2015, 61, 403-408.	5.8	100
56	Risk of progression to high-grade anal intraepithelial neoplasia in HIV-infected MSM. <i>Aids</i> , 2015, 29, 695-702.	2.2	40
57	Epidemiology and Long-Term Survival in HIV-Infected Patients With <i>Pneumocystis jirovecii</i> Pneumonia in the HAART Era. <i>Medicine (United States)</i> , 2015, 94, e681.	1.0	27
58	Darunavir and Ritonavir Total and Unbound Plasmatic Concentrations in HIV-HCV-Coinfected Patients with Hepatic Cirrhosis Compared to Those in HIV-Monoinfected Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 6782-6790.	3.2	4
59	Randomized, crossover, double-blind, placebo-controlled trial to assess the lipid lowering effect of co-formulated TDF/FTC. <i>Journal of the International AIDS Society</i> , 2014, 17, 19550.	3.0	6
60	Effectiveness of ritonavir-boosted protease inhibitor monotherapy in the clinical setting: same results as in clinical trials? The PIMOCS Study Group. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1390-1396.	3.0	19
61	Impact of an Adherence Program to Antiretroviral Treatment on Virologic Response in a Cohort of Multitreated and Poorly Adherent HIV-Infected Patients in Spain. <i>AIDS Patient Care and STDs</i> , 2014, 28, 537-542.	2.5	7
62	Effectiveness of Efavirenz Compared with Ritonavir-Boosted Protease-Inhibitor-Based Regimens as Initial Therapy for Patients with Plasma HIV-1 RNA above 100,000 Copies/ML. <i>Antiviral Therapy</i> , 2014, 19, 569-577.	1.0	8
63	Neurological opportunistic infections and neurological immune reconstitution syndrome: impact of one decade of highly active antiretroviral treatment in a tertiary hospital. <i>HIV Medicine</i> , 2013, 14, 21-30.	2.2	17
64	Assessing main death pathways in T lymphocytes from HIV infected individuals. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2013, 83A, 648-658.	1.5	13
65	Tropical Diseases Screening in Immigrant Patients with Human Immunodeficiency Virus Infection in Spain. <i>American Journal of Tropical Medicine and Hygiene</i> , 2013, 88, 1196-1202.	1.4	45
66	Simplification to dual antiretroviral therapy including a ritonavir-boosted protease inhibitor in treatment-experienced HIV-1-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 2479-2486.	3.0	24
67	Invasive Pneumococcal Disease in HIV-Infected Adults. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 59, 31-38.	2.1	17
68	Long-Term Effectiveness of First-Line Antiretroviral Therapy in a Cohort of HIV-1 Infected Patients. <i>Journal of Antivirals & Antiretrovirals</i> , 2012, 04, .	0.1	0
69	Identification of HIV-reservoir cells with reduced susceptibility to antibody-dependent immune response. <i>ELife</i> , 0, 11, .	6.0	10
70	Exploratory study of an oral screening dysplasia program for HIV-infected men who have sex with men. <i>Aids</i> , 0, Publish Ahead of Print, .	2.2	1